中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy

文献类型：期刊论文

作者Tao, Chan-Juan1; Zhang, Peng2; Zhou, Ling3; Hu, Qiao-Ying1; Chen, Xiao-Zhong1
刊名TRANSLATIONAL CANCER RESEARCH
出版日期2020-10-01
卷号9
关键词Apatinib nasopharyngeal carcinoma (NPC) recurrent or metastatic platinum-based chemotherapy toxicity
ISSN号2218-676X
DOI10.21037/tcr-20-1773
通讯作者Chen, Xiao-Zhong(chenxiaozhongzjrt@163.com)
英文摘要Background: Platinum-based chemotherapy is the standard first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (NPC); however, there is no standard regimen for those who failed first-line treatment. This study aimed to evaluate the efficacy and safety of apatinib in treating patients with recurrent/metastatic NPC who failed prior platinum-based chemotherapy. Methods: Patients aged 18-65 years with recurrent/metastatic NPC were treated with apatinib at an initial dose of 500 mg once daily and continued until disease progression, patient withdrawal, or unacceptable toxic effects. The primary endpoints were clinical benefit rate (CBR) and toxicity Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Results: Nineteen patients were enrolled in this study. At the final follow-up, the CBR was 52.6% (95% CI: 29.8-76.2%) in the intention-to-treat population. The median PFS and OS were 3.7 (95% CI: 0.6-6.8) months and 12.9 (95% CI: 9.3-16.5) months, respectively. The most common grade 3-4 adverse events (AEs) were hand-foot syndrome [3 (15.8%)], neutropenia [2 (10.5%)], proteinuria [2 (10.5%)], oral mucosal pain [2 (10.5%)], hypertension [1 (5.3%)], hyponatremia [1 (5.3%)], artery dissection [1 (5.3%)], and nasopharyngeal hemorrhage [1 (5.3%)]. A serious Al.'s was reported in one patient who died of nasopharyngeal hemorrhage. Treatment with apatinib did not significantly influence patient-reported quality-of-life, except for nausea/vomiting and pain (P<0.05). Conclusions: Apatinib achieved modest disease control with acceptable toxicity in recurrent/metastatic NPC patients pretreated with platinum-based chemotherapy.
WOS关键词PHASE-II ; CANCER ; TRIAL ; ERA
资助项目Medical Health Science and Technology Project of Zhejiang Provincial Health Commission[2020372435]
WOS研究方向Oncology
语种英语
WOS记录号WOS:000585306900052
出版者AME PUBL CO
资助机构Medical Health Science and Technology Project of Zhejiang Provincial Health Commission
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/105247]  
专题中国科学院合肥物质科学研究院
通讯作者Chen, Xiao-Zhong
作者单位1.Univ Chinese Acad Sci, Dept Radiat Oncol, Canc Hosp, Zhejiang Canc Hosp,Inst Canc & Basic Med IBMC,Chi, Hangzhou, Peoples R China
2.Univ Chinese Acad Sci, Dept Med Oncol, Canc Hosp, Zhejiang Canc Hosp,Inst Canc & Basic Med IBMC,Chi, Hangzhou, Peoples R China
3.Guangdong Med Univ, Grad Sch, Zhanjiang, Peoples R China
推荐引用方式
GB/T 7714		 Tao, Chan-Juan,Zhang, Peng,Zhou, Ling,et al. Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy[J]. TRANSLATIONAL CANCER RESEARCH,2020,9.
APA Tao, Chan-Juan,Zhang, Peng,Zhou, Ling,Hu, Qiao-Ying,&Chen, Xiao-Zhong.(2020).Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy.TRANSLATIONAL CANCER RESEARCH,9.
MLA Tao, Chan-Juan,et al."Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy".TRANSLATIONAL CANCER RESEARCH 9(2020).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。